Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,025,116 papers from all fields of science
Search
Sign In
Create Free Account
NovoTTF-100A Device
Known as:
NovoTumor Treatment Fields
, NovoTTFields
, Optune Device
Expand
A portable, battery-operated device that is used to apply low intensity, alternating electric fields, also called tumor treatment fields (TTFs…
Expand
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
NovoTTF-100A System as a treatment for Glioblastoma
A. Morrison
2018
Corpus ID: 81441076
Background: Glioblastoma is an aggressive malignant brain tumor with exceptionally poor prognosis. Currently, patients with this…
Expand
2015
2015
The evolving genomic landscape of recurrent gliomas.
Leonel Ampie
,
Yael Kusne
,
N. Sanai
World Neurosurgery
2015
Corpus ID: 12878436
2014
2014
ED-38AN UPDATED ANALYSIS OF PATIENT REGISTRY DATA ON NOVOTTF-100A ALTERNATING ELECTRIC FIELDS THERAPY FOR RECURRENT GLIOBLASTOMA
E. Wong
,
H. Engelhard
,
+8 authors
Jay-Jiguang Zhu
2014
Corpus ID: 55009018
The NovoTTF-100A System is an anticancer treatment that emits alternating electric fields, at an intensity of 1 V/cm and a…
Expand
2014
2014
P17.60NOVO-TTF 100A SYSTEM USED SUCCESSFULLY IN A PATIENT WITH A VENTRICULO-PERITONEAL SHUNT.
M. Mrugala
,
C. Graham
,
J. Rockhill
,
D. Silbergeld
2014
Corpus ID: 71939107
BACKGROUND: NovoTTF-100A system is a new modality of treatment approved for therapy of recurrent glioblastoma. Most patients with…
Expand
2014
2014
Title Clinical Practice Experience With NovoTTF-100 A ( TM ) System for Glioblastoma : The Patient Registry Dataset ( PRiDe ) Permalink
2014
Corpus ID: 54814383
s). 2010;12(suppl 4) (NO-54). 23. Wong ET, Lok E, Swanson KD, Gautam S, Engelhard HH, Lieberman F, et al. Response assessment of…
Expand
Review
2014
Review
2014
NT-25EARLY JAPANESE EXPERIENCE WITH NovoTTF-100A SYSTEM FOR RECURRENT GBM
Y. Muragaki
,
M. Nitta
,
+4 authors
I. Suzuki
2014
Corpus ID: 75911791
BACKGROUND: NovoTTF-100A System is an FDA-approved treatment for recurrent glioblastoma (GBM) and is defined as a device of high…
Expand
2013
2013
Delayed response and survival from NovoTTF-100A in recurrent GBM
J. Villano
,
Leena E. Williams
,
+5 authors
Herbert H. Engelhard
Medical Oncology
2013
Corpus ID: 8807546
We present a 48-year-old male with recurrent glioblastoma (GBM) who was enrolled in the NovoTTF-100A landmark phase III study and…
Expand
2013
2013
Safety analysis of bevacizumab plus NovoTTF-100A in patients with recurrent malignant gliomas.
G. Elzinga
,
Amy Chung
,
E. Wong
2013
Corpus ID: 198379326
2082 Background: Both bevacizumab and the NovoTTF-100A device are treatments approved by the FDA for recurrent glioblastoma. We…
Expand
Review
2013
Review
2013
Tumor treating fields - an emerging cancer treatment modality.
M. Davis
Clinical Journal of Oncology Nursing
2013
Corpus ID: 40349291
Tumor treating fields (TTFs) are an evolving new anticancer modality. The U.S. Food and Drug Administration has approved the…
Expand
2013
2013
NovoTTF-100A versus Chemotherapie
C. Nieder
Info Onkologie
2013
Corpus ID: 77702771
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE